Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in <i>BRAF</i>-mutant melanoma.Reinhard Dummer, Keith T. Flaherty, Paolo A. Ascierto et al.|Journal of Clinical Oncology|2018Cited by 30
Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with <i>BRAF</i> V600-mutant melanoma.Helen Gogas, Reinhard Dummer, Paolo A. Ascierto et al.|Journal of Clinical Oncology|2020Cited by 23
FOLFOXIRI + bevacizumab versus FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and/or <i>RAS</i>/<i>BRAFV600E-</i>mutated primary tumor: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group.Cornelis J.A. Punt, Rutger‐Jan Swijnenburg, Cornelis Verhoef et al.|Journal of Clinical Oncology|2022Cited by 14
LBA27 First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): Overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer GroupCornelis J.A. Punt, R-J. Swijnenburg, Marinde J. G. Bond et al.|Annals of Oncology|2023Cited by 10
Adverse events of special interest in the phase 3 COLUMBUS study.Helen Gogas, Keith T. Flaherty, Reinhard Dummer et al.|Journal of Clinical Oncology|2018Cited by 3